Emanuele Valtorta

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Sandra Misale, Rona Yaeger, Sebastijan Hobor et al. · Nature · 2012 · 1.9K citations · Full text

Medicine, Molecular Genetics, Oncology +16

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Giulia Siravegna, Benedetta Mussolin, Michela Buscarino et al. · Nature Medicine · 2015 · 1.1K citations · Full text

Medicine, Cancer Biology, Oncology +16

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 1K citations · Full text

Medicine, Oncology, Pharmacology +14

A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

Andrea Bertotti, Giorgia Migliardi, Francesco Galimi et al. · Cancer Discovery · 2011 · 953 citations · Full text

Medicine, Oncology, Pharmacology +17

Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Alberto Bardelli, Simona Corso, Andrea Bertotti et al. · Cancer Discovery · 2013 · 665 citations · Full text

Medicine, Cancer Biology, Oncology +16